Cantor Fitzgerald Downgrades ADMA Biologics to Neutral from Overweight
Cantor Fitzgerald downgraded ADMA Biologics Inc. (ADMA) to Neutral from Overweight on March 26, citing concerns over channel stuffing allegations, lack of clarity in the company's response, and rising days' sales outstanding. The downgrade followed a short report by Culper Research, which ADMA refuted as unsubstantiated. ADMA's stock dropped 14.7% week-over-week as three executives sold shares.
Tickers: $ADMA
Topics: ADMA Biologics analyst action biotech Cantor Fitzgerald stock downgrade